Yiwei Wang, Yang Liu, Xuezeng, Mengen Zhai, Xin Meng, Ping Jin, Fanglin Lu, Jian Yang
{"title":"经导管三尖瓣置换术与全胸腔镜心脏搏动手术治疗三尖瓣反流。","authors":"Yiwei Wang, Yang Liu, Xuezeng, Mengen Zhai, Xin Meng, Ping Jin, Fanglin Lu, Jian Yang","doi":"10.1007/s10557-025-07669-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Totally thoracoscopic and beating-heart techniques used in tricuspid valve surgery (TTC-TVS) show favorable outcomes. Transcatheter tricuspid valve replacement (TTVR) is an increasingly utilized alternative for patients with tricuspid regurgitation (TR) at high surgical risk. The purpose of this study was to compare TTVR with TTC-TVS to examine the outcomes of these two different management protocols for patients with symptomatic severe TR.</p><p><strong>Methods: </strong>A total of 116 patients with symptomatic severe TR were retrospectively collected and divided into the TTVR (n = 38) and the TTC-TVS (n = 78) groups. The primary end points included 2-year all-cause mortality and the combined endpoint (all-cause mortality and hospitalizations for heart failure).</p><p><strong>Results: </strong>At a median follow-up of 630 (IQR 450-720) days, the similar freedom from 2-year all-cause mortality (85.2% vs. 70.8%; log-rank P = 0.13) and different freedom from combined endpoint (75.3% vs. 49.8%; log-rank P = 0.0049) were followed in TTVR and TTC-TVS. After stratification by TRI-SCORE, TTVR subgroups showed significant difference in combined endpoint, and both also showed significant difference compared to the corresponding TTC-TVS subgroups (all log-rank P < 0.05). In multivariate Cox regression analysis, TRI-SCORE ≥ 6 was independently correlated with all-cause mortality (HR 3.913, 95% CI 1.481-10.337; P = 0.006) and combined endpoint (HR 4.070, 95% CI 1.924-8.608; P < 0.001).</p><p><strong>Conclusions: </strong>TTVR may offer greater benefit compared to TTC-TVS for sicker patients with severe TR. However, this observation should be interpreted within a specific clinical context emphasizing the importance of early intervention.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transcatheter Tricuspid Valve Replacement Versus Totally Thoracoscopic Beating-Heart Surgery for Tricuspid Regurgitation.\",\"authors\":\"Yiwei Wang, Yang Liu, Xuezeng, Mengen Zhai, Xin Meng, Ping Jin, Fanglin Lu, Jian Yang\",\"doi\":\"10.1007/s10557-025-07669-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Totally thoracoscopic and beating-heart techniques used in tricuspid valve surgery (TTC-TVS) show favorable outcomes. Transcatheter tricuspid valve replacement (TTVR) is an increasingly utilized alternative for patients with tricuspid regurgitation (TR) at high surgical risk. The purpose of this study was to compare TTVR with TTC-TVS to examine the outcomes of these two different management protocols for patients with symptomatic severe TR.</p><p><strong>Methods: </strong>A total of 116 patients with symptomatic severe TR were retrospectively collected and divided into the TTVR (n = 38) and the TTC-TVS (n = 78) groups. The primary end points included 2-year all-cause mortality and the combined endpoint (all-cause mortality and hospitalizations for heart failure).</p><p><strong>Results: </strong>At a median follow-up of 630 (IQR 450-720) days, the similar freedom from 2-year all-cause mortality (85.2% vs. 70.8%; log-rank P = 0.13) and different freedom from combined endpoint (75.3% vs. 49.8%; log-rank P = 0.0049) were followed in TTVR and TTC-TVS. After stratification by TRI-SCORE, TTVR subgroups showed significant difference in combined endpoint, and both also showed significant difference compared to the corresponding TTC-TVS subgroups (all log-rank P < 0.05). In multivariate Cox regression analysis, TRI-SCORE ≥ 6 was independently correlated with all-cause mortality (HR 3.913, 95% CI 1.481-10.337; P = 0.006) and combined endpoint (HR 4.070, 95% CI 1.924-8.608; P < 0.001).</p><p><strong>Conclusions: </strong>TTVR may offer greater benefit compared to TTC-TVS for sicker patients with severe TR. However, this observation should be interpreted within a specific clinical context emphasizing the importance of early intervention.</p>\",\"PeriodicalId\":9557,\"journal\":{\"name\":\"Cardiovascular Drugs and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Drugs and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10557-025-07669-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07669-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的:全胸腔镜和心脏跳动技术应用于三尖瓣手术(TTC-TVS)显示良好的效果。经导管三尖瓣置换术(TTVR)是三尖瓣返流(TR)高手术风险患者越来越多使用的替代方法。本研究的目的是比较TTVR和TTC-TVS两种不同的治疗方案对有症状的严重TR患者的治疗效果。方法:回顾性收集116例有症状的严重TR患者,分为TTVR组(n = 38)和TTC-TVS组(n = 78)。主要终点包括2年全因死亡率和联合终点(全因死亡率和心力衰竭住院)。结果:在中位随访630 (IQR 450-720)天时,2年全因死亡率的相似自由度(85.2% vs. 70.8%;log-rank P = 0.13)和联合终点的不同自由度(75.3% vs. 49.8%;log-rank P = 0.0049), TTVR和TTC-TVS随访。经TRI-SCORE分层后,TTVR亚组在联合终点上显示出显著差异,与相应的TTC-TVS亚组相比,两者也显示出显著差异(均为log-rank P)。结论:对于病情较重的严重TR患者,TTVR可能比TTC-TVS提供更大的益处。然而,这一观察结果应在特定的临床背景下进行解释,强调早期干预的重要性。
Transcatheter Tricuspid Valve Replacement Versus Totally Thoracoscopic Beating-Heart Surgery for Tricuspid Regurgitation.
Purpose: Totally thoracoscopic and beating-heart techniques used in tricuspid valve surgery (TTC-TVS) show favorable outcomes. Transcatheter tricuspid valve replacement (TTVR) is an increasingly utilized alternative for patients with tricuspid regurgitation (TR) at high surgical risk. The purpose of this study was to compare TTVR with TTC-TVS to examine the outcomes of these two different management protocols for patients with symptomatic severe TR.
Methods: A total of 116 patients with symptomatic severe TR were retrospectively collected and divided into the TTVR (n = 38) and the TTC-TVS (n = 78) groups. The primary end points included 2-year all-cause mortality and the combined endpoint (all-cause mortality and hospitalizations for heart failure).
Results: At a median follow-up of 630 (IQR 450-720) days, the similar freedom from 2-year all-cause mortality (85.2% vs. 70.8%; log-rank P = 0.13) and different freedom from combined endpoint (75.3% vs. 49.8%; log-rank P = 0.0049) were followed in TTVR and TTC-TVS. After stratification by TRI-SCORE, TTVR subgroups showed significant difference in combined endpoint, and both also showed significant difference compared to the corresponding TTC-TVS subgroups (all log-rank P < 0.05). In multivariate Cox regression analysis, TRI-SCORE ≥ 6 was independently correlated with all-cause mortality (HR 3.913, 95% CI 1.481-10.337; P = 0.006) and combined endpoint (HR 4.070, 95% CI 1.924-8.608; P < 0.001).
Conclusions: TTVR may offer greater benefit compared to TTC-TVS for sicker patients with severe TR. However, this observation should be interpreted within a specific clinical context emphasizing the importance of early intervention.
期刊介绍:
Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.
Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.
Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.